On this page

What is Portal Hypertension?
Portal Circulation and Systemic Circulation
Causes and Classification
Symptoms
Complications
Diagnosis
Treatment
Sources and Bibliography

What is Portal Hypertension?

Portal hypertension is a serious condition that develops as a consequence of advanced liver disease (hepatopathy). In developed countries, it is most frequently caused by cirrhosis, a chronic, progressive disease that leads to fibrosis and structural distortion of the liver. This causes profound alterations in hepatic blood flow.

To understand portal hypertension, it is essential to grasp the anatomy and physiology of the portal vein, a large abdominal vein that carries nutrient-rich blood from the intestine to the liver. Within the liver, the portal vein branches into an intricate network of small venules before draining into the hepatic veins, which lead to the inferior vena cava and ultimately to the heart.

The pressure within the portal venous system depends on two key variables:

The volume of blood arriving at the liver
The resistance the liver opposes to blood flow

Under normal physiological conditions, portal vein pressure ranges from 5 to 10 mmHg and is 4 to 5 mmHg higher than the pressure in the inferior vena cava. This difference is known as the portal pressure gradient (or hepatic venous pressure gradient, HVPG).

Portal hypertension is defined as a portal pressure gradient of at least 5 mmHg above inferior vena cava pressure (i.e., HVPG ≥ 5 mmHg). Clinically significant portal hypertension is defined at HVPG ≥ 10 mmHg, which is the threshold at which major complications begin to develop.

This pressure elevation may result from:

Intrinsic liver disease, distorting intrahepatic vascular architecture
Obstruction anywhere along the portal system, from its splanchnic origin (intestine, pancreas, and spleen) through the liver to the hepatic veins and inferior vena cava
Increased blood flow into the portal venous system (less common)

The prognosis of portal hypertension depends on the stage of the underlying liver disease, the degree of pressure elevation, and the severity of its complications.

Portal Circulation and Systemic Circulation

The portal and systemic circulations work in parallel to fulfill two fundamental functions:

Cleansing the blood of metabolic waste products
Returning blood to the heart for oxygenation and redistribution to all organs

The portal vein is a major abdominal vessel that drains blood from the splanchnic territory (the intestine, pancreas, and spleen) into the liver. The liver is the principal organ responsible for metabolizing and detoxifying substances absorbed during digestion.

In quantitative terms, the liver receives approximately 1.5 liters of blood per minute:

70% from the portal vein (nutrient-rich, partially deoxygenated)
30% from the hepatic artery (fully oxygenated, from the systemic circulation)

Within the liver, portal and arterial blood converge into structures called hepatic sinusoids, which are microscopic, highly specialized channels lined by fenestrated endothelial cells and Kupffer cells. These channels are designed to facilitate molecular filtration and metabolic exchange.

After filtration, blood is drained into the systemic circulation through the hepatic veins and the inferior vena cava, and returned to the heart for oxygenation through the lungs.

Given its critical metabolic role, the liver is protected by several homeostatic mechanisms that maintain stable hepatic blood flow:

The dual blood supply (portal and arterial) protects the liver against hypoxemia and ischemic injury
Under normal conditions, sinusoidal pressure remains stable regardless of fluctuations in blood flow volume
The hepatic artery buffer response: hepatic arterial flow is inversely proportional to portal flow. If portal pressure drops (e.g., due to splanchnic vasodilation), arterial flow automatically compensates to maintain total hepatic perfusion

These protective mechanisms are progressively overwhelmed in chronic liver disease, setting the stage for portal hypertension.

Causes and Classification

Portal hypertension is the most clinically significant consequence of chronic liver disease, particularly cirrhosis. Cirrhosis causes fibrosis and architectural distortion of the hepatic sinusoids, dramatically increasing intrahepatic vascular resistance and preventing normal portal blood flow.

Portal hypertension is classified anatomically into three categories based on the location of the obstruction relative to the liver:

Pre-Hepatic Portal Hypertension

The obstruction lies between the splanchnic bed and the hepatic hilum (the entry point of the portal vein into the liver). Causes include:

Arteriovenous malformations of the spleen
Splenomegaly (enlargement of the spleen) with increased splenic blood flow
Portal vein thrombosis

Intra-Hepatic Portal Hypertension

The obstruction lies within the liver parenchyma itself. This is the most common category and includes:

Liver cirrhosis (the leading cause worldwide)
Primary biliary cholangitis
Sarcoidosis
Congenital hepatic fibrosis
Schistosomiasis (a major cause in endemic regions)
Hepatitis B and Hepatitis C
Hemochromatosis
Alpha-1 antitrypsin deficiency
Hepatic veno-occlusive disease (sinusoidal obstruction syndrome)

Post-Hepatic Portal Hypertension

The obstruction lies between the hepatic veins and the right atrium of the heart. Causes include:

Cardiac diseases such as constrictive pericarditis and restrictive cardiomyopathy
Budd-Chiari syndrome (thrombosis of the hepatic veins)
Obstruction or compression of the inferior vena cava

Symptoms

Because portal hypertension is fundamentally a consequence of underlying liver disease, its clinical presentation is largely shaped by the signs and symptoms of hepatic dysfunction more broadly:

Hepatomegaly (liver enlargement), variable in degree depending on the cause and disease stage
Low-grade fever, common in inflammatory and infectious hepatopathies
Fatigue and general malaise
Anorexia and weight loss
Nausea and vomiting, dyspepsia (impaired digestion)
Signs of cholestasis (obstruction of bile flow within intrahepatic or extrahepatic bile ducts):
- Jaundice (yellowing of the skin and sclera)
- Pruritus (generalized itching)
- Dark urine and pale stools
Coagulation abnormalities: impaired synthesis of clotting factors leads to easy bruising and bleeding
In men: hormonal imbalances due to the liver’s inability to metabolize sex hormones may cause:
- Gynecomastia (breast tissue enlargement)
- Testicular atrophy
- Erectile dysfunction and impotence
Protein loss and hypoalbuminemia leading to:
- Muscle cramps
- Muscle weakness and wasting
- Peripheral edema (leg swelling)

Complications

Clinically significant portal hypertension (HVPG ≥ 10 mmHg) may be difficult to detect in subclinical stages. Unfortunately, in many cases, the condition is only recognized once major complications have already developed. These complications are themselves leading causes of morbidity and mortality in patients with chronic liver disease and, in advanced cases, indications for liver transplantation.

As portal pressure rises, the body attempts to decompress the system by forming portosystemic collateral vessels, which are alternative venous pathways that divert portal blood into the systemic circulation, bypassing the obstructed liver. While initially protective, these collaterals become dangerous when the underlying cause is not corrected.

Portosystemic Varices

Gastroesophageal varices: the most common and most dangerous collateral vessels. They are dilated, tortuous submucosal vessels that protrude into the gastric and esophageal lumen. They rupture spontaneously in more than 50% of cases, causing life-threatening hemorrhage.
Rectal varices: may cause symptoms resembling hemorrhoidal disease and bleeding.
Caput medusae: a visible network of dilated periumbilical veins that radiate outward from the navel, a classic physical examination finding in portal hypertension.
Spider angiomas (spider naevi): small, superficial dilated venules visible beneath the skin surface, particularly on the upper chest and face.

Congestive Portal Hypertensive Gastropathy

Altered portal and systemic circulation renders the gastric mucosa more fragile and prone to bleeding, independent of variceal rupture.

Gastrointestinal Hemorrhage from Variceal Rupture

This is among the most dangerous and potentially fatal complications of portal hypertension, and may be its first clinical presentation. Key features include:

Sudden, profuse, painless bleeding
Pallor
Cyanosis of the lips, tongue, and extremities
Hematemesis (vomiting of bright red blood)
Melena (black, tarry stools from digested blood in the intestinal lumen)
Hematochezia (bright red blood in stool, typically from rectal or hemorrhoidal bleeding)

Hepatic Encephalopathy and Hepatic Coma

When portal blood bypasses the liver and enters the systemic circulation directly, neurotoxic substances (particularly ammonia) accumulate and reach the brain. Clinical manifestations progress through stages:

Sleep-wake cycle disturbances
Cognitive impairment and memory loss
Communication difficulties
Personality changes and inappropriate behavior
Fetor hepaticus: a distinctive sweet-musty breath odor caused by volatile aromatic compounds entering the pulmonary circulation
In severe cases, progression to stupor and coma

Splenomegaly and Hypersplenism

Congestion of the splanchnic circulation causes splenic enlargement and subsequent hypersplenism (overactivity of the spleen), leading to excessive sequestration of blood cells:

Thrombocytopenia (low platelet count), which increases bleeding risk
Leukopenia (low white blood cell count), which increases infection risk
Hemolytic anemia (destruction of red blood cells)

Ascites

Ascites refers to the accumulation of lymphatic fluid in the peritoneal cavity (the space lined by the peritoneum, surrounding abdominal organs). Under normal conditions, lymphatic fluid remains within hepatic lymphatic vessels. However, elevated portal pressure causes fluid to extravasate into the interstitial space and accumulate in the abdomen.

Clinical features depend on the volume of fluid and may include:

Abdominal distension and increased abdominal girth
Umbilical hernia (due to increased intra-abdominal pressure)
Dyspnea (breathing difficulty, caused by diaphragmatic compression)
Fever, if the ascitic fluid becomes infected (a complication known as spontaneous bacterial peritonitis (SBP)), which is a life-threatening emergency

Hepatorenal Syndrome

In advanced stages of hepatic insufficiency, profound hemodynamic alterations lead to functional renal failure. This condition, known as hepatorenal syndrome, is characterized by intense splanchnic vasodilation and renal vasoconstriction in the absence of structural kidney disease.

Portal Vein Thrombosis

Blood stasis and fragility of hepatic sinusoids predispose patients to thrombosis of the portal vein itself, further worsening portal hypertension.

Flapping Tremor (Asterixis)

A characteristic hand tremor observed when the wrists are extended, resembling the flapping of a bird’s wings, is considered a neurological sign of hepatic encephalopathy.

Diagnosis

The diagnosis of portal hypertension is multimodal, integrating clinical findings, laboratory data, imaging studies, and endoscopy.

Laboratory Tests

A comprehensive panel typically includes:

Complete blood count (CBC) with platelet count to identify thrombocytopenia, leukopenia, and hemolytic anemia
Liver function tests (transaminases) and cholestasis markers (bilirubin, alkaline phosphatase, gamma-GT)
Serum albumin, a marker of synthetic liver function and nutritional status
Renal function tests: serum creatinine and urea
Electrolytes, including sodium and potassium (important for management of ascites), play a key role in bodily functions
Serological markers for hepatitis B and C
Coagulation studies (PT/INR)

Clinical Assessment

Subclinical portal hypertension is often clinically silent and may only become apparent through the development of complications. A thorough physical examination may reveal hepatomegaly, splenomegaly, caput medusae, spider angiomas, ascites, and peripheral edema.

Imaging Studies

Abdominal ultrasound with Doppler flow analysis (color Doppler ultrasonography) is the primary and most informative non-invasive diagnostic tool. It provides detailed information on:

Direction and velocity of portal blood flow (reversal of flow, also known as hepatofugal, is a hallmark of advanced portal hypertension)
Liver and spleen size
Portal vein diameter (dilation is a key indicator)
Presence of thrombosis
Development of portosystemic collateral vessels and ascites

Additional imaging modalities may include:

CT angiography or MRI can be used for detailed vascular mapping, especially when planning surgical or interventional procedures
Transient elastography (FibroScan) is a non-invasive method that estimates liver stiffness. This measurement correlates with the degree of fibrosis and portal pressure

Endoscopy

Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) is the gold standard for the diagnosis and management of acute gastrointestinal bleeding from varices. Beyond providing a definitive diagnosis, it allows for immediate therapeutic intervention to control active hemorrhage.

Invasive Pressure Measurement

Hepatic venous pressure gradient (HVPG) measurement, performed by inserting a catheter through the jugular vein into the hepatic veins, remains the gold standard for directly quantifying portal hypertension. It also guides prognosis and monitors treatment response. It is particularly valuable in clinical research and in complex diagnostic situations.

Treatment

The primary goal of therapy in portal hypertension is to prevent the development and progression of complications. Lowering pressure alone is often technically difficult to achieve and sustain, so the focus remains on managing these risks instead. Treatment of the underlying liver disease is paramount whenever possible.

Liver transplantation remains the only definitive treatment for advanced hepatic disease with portal hypertension, particularly in patients with hepatic insufficiency, encephalopathy, or hepatorenal syndrome.

Diet

Dietary modifications are a fundamental component of managing portal hypertension and should be considered alongside all pharmacological and procedural treatments:

Eliminating or drastically reducing alcohol intake: Alcohol is a primary driver of progressive liver damage and must be avoided in all patients with alcoholic liver disease.
Restricting sodium (salt) intake to less than 2 grams of sodium per day helps control fluid retention and ascites. Patients should be counseled that industrial and processed foods contain far more sodium than commonly appreciated.
Protein modulation: In patients with overt hepatic encephalopathy, targeted protein restriction may be indicated. However, this should be carefully supervised to avoid malnutrition, as it worsens prognosis.

Treatment of Varices

Management is aimed at stopping acute bleeding and preventing recurrence (secondary prophylaxis), as well as preventing a first bleed in patients with known high-risk varices (primary prophylaxis).

Pharmacological Therapy

Non-selective beta-blockers (propranolol, carvedilol, nadolol): reduce portal pressure by decreasing cardiac output and promoting splanchnic vasoconstriction. They are the cornerstone of primary prophylaxis for variceal bleeding.
Vasopressin analogues (terlipressin) and somatostatin analogues (octreotide): cause splanchnic vasoconstriction and are used in acute variceal bleeding to reduce portal inflow.
Antibiotic therapy (norfloxacin, ceftriaxone): reduces the risk of re-bleeding and bacterial infections (spontaneous bacterial peritonitis) that commonly complicate acute hemorrhage, and has been shown to improve overall survival.

Endoscopic Interventions

Endoscopic variceal ligation (EVL): the preferred endoscopic technique, in which a rubber band is applied around the base of each varix to cut off blood supply, causing it to necrose and slough off. It is the first-line treatment for acute variceal bleeding and for primary and secondary prophylaxis.
Sclerotherapy: injection of sclerosing agents (e.g., sodium tetradecyl sulfate) directly into or adjacent to varices to induce thrombosis and fibrosis. Now largely replaced by EVL but still used in some settings.
Balloon tamponade (Sengstaken-Blakemore tube) is a temporizing measure for massive, refractory variceal hemorrhage. This procedure involves inflating a balloon in the stomach or esophagus to mechanically compress bleeding varices. Reserved for salvage situations, as it carries significant complication risks.

Shunting Procedures

When patients fail pharmacological and endoscopic management:

Transjugular Intrahepatic Portosystemic Shunt (TIPS/TIPSS): a minimally invasive radiological procedure in which an expandable metal stent is placed within the liver to create a direct communication between the portal vein and a hepatic vein, effectively bypassing the diseased hepatic parenchyma and lowering portal pressure. TIPS is highly effective at controlling refractory variceal bleeding and ascites, but carries risk of worsening hepatic encephalopathy.
Surgical portocaval shunt: a surgical anastomosis between the portal and systemic venous systems. Largely replaced by TIPS in current practice, but may still be considered in selected patients at specialized centers.

Treatment of Ascites

Management of ascites follows a stepwise approach:

Dietary Restriction

Sodium restriction to less than 2 grams per day is the cornerstone of ascites management and alone may be sufficient in mild cases
Fluid restriction is generally not required unless dilutional hyponatremia (serum sodium < 125–130 mEq/L) develops

Diuretic Therapy

A combination of:

Spironolactone (an aldosterone antagonist) is the first-line agent. It addresses the hyperaldosteronism that drives sodium retention in cirrhosis
Furosemide (a loop diuretic) is often added to spironolactone for enhanced effect

Patients on diuretics require regular monitoring of electrolytes, renal function, and blood pressure to detect complications such as hyponatremia, hypokalemia, renal impairment, and orthostatic hypotension.

Large Volume Paracentesis (LVP)

In patients with refractory or tense ascites (not adequately controlled by medications), or in those who cannot tolerate diuretics, paracentesis is performed: a sterile needle is inserted into the abdominal cavity under ultrasound guidance to drain the accumulated fluid. When large volumes (> 5 liters) are removed, intravenous albumin infusion is recommended to prevent post-paracentesis circulatory dysfunction.

TIPS for Refractory Ascites

In patients with frequently recurring refractory ascites requiring repeated paracentesis, TIPS may be considered to reduce portal pressure and improve ascites control, particularly when liver transplantation is being evaluated.

Portal Hypertension: Symptoms, Diagnosis, and Treatment